It is truly astonishing, also considering that there must be employees who know what is going on? How do they manage to keep such a tight control on any wistleblowing?
Your description of the challenges of fairly assessing the benefits (and particularly harms) of new drug treatments is accurate it is profoundly sad. You seem to describe pharma companies who fail to openly publish important data and regulators who don't have the resources find it. Is this correct? Could the benefits and risks of other widely used medicines (used to prevent disease) be similarly poorly understood?
Hi Keith, yes, in a nutsheell. Scan quickly the antivirals story and you’ll see history repeating itself time and time again.
Best, Tom
It is truly astonishing, also considering that there must be employees who know what is going on? How do they manage to keep such a tight control on any wistleblowing?
Your description of the challenges of fairly assessing the benefits (and particularly harms) of new drug treatments is accurate it is profoundly sad. You seem to describe pharma companies who fail to openly publish important data and regulators who don't have the resources find it. Is this correct? Could the benefits and risks of other widely used medicines (used to prevent disease) be similarly poorly understood?